Figure 3 . The curve of concentrations of P. nagi kernel
and DPPH scavenging ability
3.4.2 Preliminary in vitro anticancer evaluation
The preliminary in vitro anticancer result ofP. nagi kernel oil against
gastric cancer, breast cancer (MCF-7), lung cancer(A549) and Hela cell
lines listed in table 6 . It showed that P. nagi kernel
oil exhibited stronger anticancer activity against these four cancer
cell lines: the anticancer efficacy against gastric cancer cell lines is
in a concentration-dependent manner from 0.78125 to 25mg/mL, and the
highest inhibition is 64.30%±2.80 with IC50=48.47mg/mL;
the anticancer efficacy against lung cancer(A549) cell lines is in a
concentration-dependent manner from 0.78125 to 50mg/mL, and the highest
inhibition is 93.21%±2.24 with IC50=11.47mg/mL; the
anticancer efficacy against breast cancer(MCF-7) cell lines is in a
concentration-dependent manner from 0.78125 to 25mg/mL, and the highest
inhibition is 52.86%±2.57 with IC50=736.14mg/mL; while
the anticancer efficacy against Hela cell lines is in a
concentration-dependent manner from 0.78125 to 50mg/mL, and the highest
inhibition is 85.33%±3.03 with IC50=23.77mg/mL. The
results imply that this oil can be also regarded as the anticancer
agent.
Table 6 . Preliminary in vitro anticancer results